Patents by Inventor Rina Aharoni
Rina Aharoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200397853Abstract: A method of treating a heart disease in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide and a Copolymer 1-related peptide, thereby treating the heart disease.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicant: Yeda Research and Development Co. Ltd.Inventors: Eldad TZAHOR, Ruth ARNON, Rachel SARIG, Rina AHARONI, Kfir Baruch UMANSKY
-
Publication number: 20150030560Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: February 24, 2014Publication date: January 29, 2015Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20120135016Abstract: A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent.Type: ApplicationFiled: October 26, 2011Publication date: May 31, 2012Inventors: Michal Eisenbach-Schwartz, Ruth Arnon, Oleg Butovsky, Yaniv Ziv, Jonathan Kipnis, Noga Ron, Raya Eijam, Rina Aharoni
-
Patent number: 8008258Abstract: The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.Type: GrantFiled: January 20, 2004Date of Patent: August 30, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Rina Aharoni, Ruth Arnon, Basak Kayhan
-
Publication number: 20100298227Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: August 29, 2008Publication date: November 25, 2010Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Publication number: 20090191173Abstract: A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent.Type: ApplicationFiled: November 29, 2005Publication date: July 30, 2009Inventors: Michal Eisenbach-Schwartz, Ruth Arnon, Oleg Butovsky, Yaniv Ziv, Jonathan Kipnis, Noga Ron, Raya Eilam, Rina Aharoni
-
Patent number: 7560100Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.Type: GrantFiled: September 9, 2005Date of Patent: July 14, 2009Assignee: Yeda Research and Development Co., Ltd.Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni
-
Patent number: 7425332Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: GrantFiled: September 27, 2006Date of Patent: September 16, 2008Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard UniversityInventors: Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
-
Patent number: 7279172Abstract: The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.Type: GrantFiled: January 23, 2001Date of Patent: October 9, 2007Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard CollegeInventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
Publication number: 20070054857Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.Type: ApplicationFiled: September 29, 2006Publication date: March 8, 2007Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni -
Publication number: 20070021341Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: September 27, 2006Publication date: January 25, 2007Inventors: Michael Sela, Masha Fridkis-Hareli, Jack Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
-
Publication number: 20060276390Abstract: Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for the treatment of graft rejection using ordered peptides or ordered copolymer 1-related heteropolymers as monotherapy are also provided.Type: ApplicationFiled: August 4, 2006Publication date: December 7, 2006Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MOR RESEARCH APPLICATIONS LTD.Inventors: Rina Aharoni, Ruth Arnon, Michael Sela, Alex Yussim
-
Publication number: 20060264354Abstract: The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.Type: ApplicationFiled: January 20, 2004Publication date: November 23, 2006Inventors: Rina Aharoni, Ruth Arnon, Basak Kayhan
-
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
Publication number: 20060122113Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.Type: ApplicationFiled: September 9, 2005Publication date: June 8, 2006Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni -
Patent number: 7053043Abstract: Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.Type: GrantFiled: November 12, 1999Date of Patent: May 30, 2006Assignee: Yeda Research and Development Co.Ltd.Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
-
Publication number: 20020055466Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.Type: ApplicationFiled: January 23, 2001Publication date: May 9, 2002Inventors: Rina Aharoni, Dvora Teitelbaum, Ruth Arnon, Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger
-
Patent number: 5858964Abstract: Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.Type: GrantFiled: October 6, 1995Date of Patent: January 12, 1999Assignees: Yeda Research and Development Co. Ltd., Board of Trustees of the Leland Stanford Junior UniversityInventors: Rina Aharoni, Ruth Arnon, Nelson J. Chao, Paul G. Schlegel, Michael Sela, Dvora Teitelbaum